The discovery of a protective natural IgA human monoclonal antibody against LpqH, a major virulence factor in Mtb pathogenesis, from a naturally exposed asymptomatic donor, opens new avenues in TB vaccine development and prophylaxis.
Successful immunisation studies in monkeys based on MSP1 involved the use of the full-length protein as a malaria vaccine. However, unsuccessful human trials only tested MSP1 subunits. We explore the potential of SumayaVac-1 to broadly stimulate immune mechanisms associated with protection.
What are we missing? Comparing the immunoproteomes of enterotoxigenic E. coli infected and vaccinated hosts can yield insights for rational vaccine design.